# KSQ-4279

Source: https://onco.cc/drugs/ksq-4279/  
OnCo record `ksq-4279` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

KSQ-4279 is an experimental drug from KSQ Therapeutics, in phase 1 trials for advanced solid tumours.

## Summary

KSQ-4279 is a small molecule from KSQ Therapeutics. A selective inhibitor of USP1, an enzyme that helps regulate the repair of damaged DNA. KSQ licensed it worldwide to Roche in July 2023, and the registry now names it RO7623066. Its completed phase 1 study (NCT05240898) tested it alone and with olaparib or carboplatin. OnCo has no USP1 target record. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Also known as: RO7623066; RG6614
- Tags: pipeline; ctgov-ingest
- Code: KSQ-4279
- Modality: Small molecule
- Mechanism: A selective inhibitor of USP1, an enzyme that helps regulate the repair of damaged DNA.

## Sources

- KSQ Therapeutics pipeline: https://ksqtx.com/pipeline/
- KSQ Therapeutics partners: https://ksqtx.com/partners/
- ClinicalTrials.gov NCT05240898: https://clinicaltrials.gov/study/NCT05240898

## Connected records

- companies: [KSQ Therapeutics](https://onco.cc/companies/ksq-therapeutics/)
- trials: [A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05240898/)

---
JSON: https://onco.cc/api/v1/entities/ksq-4279.json